These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32389446)

  • 1. Reply to Can Lu and Xiao Guan's Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022.
    Babjuk M
    Eur Urol; 2020 Aug; 78(2):e73-e74. PubMed ID: 32389446
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022.
    Lu C; Guan X
    Eur Urol; 2020 Aug; 78(2):e71-e72. PubMed ID: 32389445
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Ola Bratt and Anna Öfverholm's Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028.
    Eklund M; Ström P; Nordström T; Grönberg H
    Eur Urol; 2018 Jul; 74(1):e10-e11. PubMed ID: 29598984
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
    Liedberg F; Kollberg P; Allerbo M; Baseckas G; Brändstedt J; Gudjonsson S; Hagberg O; Håkansson U; Jerlström T; Löfgren A; Patschan O; Sörenby A; Bläckberg M
    Eur Urol; 2020 Nov; 78(5):e186-e187. PubMed ID: 32950295
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Bexultan Kazybay and Yingqiu Xie's Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024.
    Coelingh Bennink HJT; Foidart JM; Debruyne FMJ
    Eur Urol; 2021 Nov; 80(5):e117-e118. PubMed ID: 34509303
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Valle LF; Kishan AU
    Eur Urol; 2021 Jul; 80(1):e15-e16. PubMed ID: 33934928
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
    Chesnut GT; Vertosick EA; Ehdaie B
    Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012.
    Kerkmeijer LGW; Pos FJ; van der Heide UA; Israël B; Draulans C; Haustermans K
    Eur Urol; 2022 Jun; 81(6):e147-e148. PubMed ID: 35339319
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
    Ahmadzadehfar H; Essler M
    Eur Urol; 2019 Nov; 76(5):e126-e127. PubMed ID: 31151676
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Loehr A; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
    Wilkinson S; Ye H; Lis RT; Sowalsky AG
    Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory.
    Sathianathen NJ; Konety BR
    Eur Urol; 2019 Jul; 76(1):e10-e11. PubMed ID: 30665809
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Tomlins SA; Groskopf J; Chinnaiyan AM
    Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolás Badillo's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009.
    Ilie G; David Harold Rutledge R
    Eur Urol; 2023 Jul; 84(1):e26-e27. PubMed ID: 37127468
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.
    Becker REN; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Feb; 79(2):e58-e59. PubMed ID: 33218822
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Nadir I. Osman, Christopher R. Chapple, Sheila MacNeil's Letter to the Editor re: Guido Barbagli, Massimo Lazzeri. Clinical Experience with Urethral Reconstruction Using Tissue-engineered Oral Mucosa: A Quiet Revolution. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.043.
    Barbagli G; Lazzeri M
    Eur Urol; 2015 Nov; 68(5):e101-2. PubMed ID: 26260002
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
    Stopsack KH
    Eur Urol; 2021 Mar; 79(3):e81-e82. PubMed ID: 33358233
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Glen Denmer Santok and Koon Ho Rha's Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023.
    Stattin P; Bratt O
    Eur Urol; 2017 Apr; 71(4):e115-e116. PubMed ID: 27720538
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
    Gandaglia G; Sun M; Briganti A; Karakiewicz PI
    Eur Urol; 2014 Aug; 66(2):e36-7. PubMed ID: 24746970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.